Orteronel
Orteronel (TAK-700) is a highly selective inhibitor of human 17,20-lyase (CYP17) with IC50 of 38 nM, and exhibits >1000-fold selectivity over other CYPs such as 11-hydroxylase and CYP3A4[1][2].
Product Specifications
CAS Number
566939-85-3
Product Name Alternative
TAK-700
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Orteronel.html
Concentration
10mM
Purity
99.90
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C2C=C([C@@]3(O)CCN4C=NC=C43)C=CC2=C1)NC
Molecular Formula
C18H17N3O2
Molecular Weight
307.35
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Yamaoka M, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
 J Steroid Biochem Mol Biol. 2012 Apr;129 (3-5) :115-28.|[2]Kaku, Tomohiro., et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. From Bioorganic & Medicinal Chemistry (2011), 19 (21), 6
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
CYP17
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CA233-C8-AQ 3 µm
Caprisil C8-AQ HPLC Column, 3 µm, 100 Å, CA533-C8-AQ x 50 mm
Sign In for Pricing
View Details